1. The Durability of EUS-Guided Chemoablation of Mucinous Pancreatic Cysts: A Long-Term Follow-Up of the CHARM trial
- Author
-
Jennifer L. Maranki, Niraj J. Gusani, Charles Dye, Heather D. Heisey, Abraham Mathew, Kayla M. Hartz, Leonard Walsh, Courtney Lester, Brandy D. Headlee, John M. Levenick, Matthew E.B. Dixon, Matthew T. Moyer, and James H. Birkholz
- Subjects
Surgical resection ,medicine.medical_specialty ,Hepatology ,business.industry ,Long term follow up ,Gastroenterology ,Malignancy ,medicine.disease ,Article ,Pancreatic Neoplasms ,stomatognathic diseases ,Concomitant ,Pancreatic cancer ,medicine ,Humans ,Radiology ,Pancreatic Cyst ,Pancreatic cysts ,business ,Carcinoma, Pancreatic Ductal ,Follow-Up Studies - Abstract
Pancreatic cancer has known precursor lesions with potential to develop into malignancy over time. At least 20% of pancreatic cancer evolves from mucinous cystic neoplasms and intraductal papillary mucinous neoplasms, which are often discovered incidentally.1,2 Current guidelines for the management of mucinous cystic neoplasms and intraductal papillary mucinous neoplasms include long-term surveillance, which is expensive and nontherapeutic, or surgical resection, which is associated with major risk and may not be an option for patients with significant concomitant illness.3.
- Published
- 2022
- Full Text
- View/download PDF